GI
NAVB

Gradient Investments’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Gradient Investments’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-31
Closed – – 1327
2019
Q4 		$0 Buy
+31
New +$27 ﹤0.01% 1321

Other funds holding NAVB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
ACM
Allred Capital Management Dallas, Texas $275M AUM 18.19% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Wolverine Trading
Wolverine Trading Chicago, Illinois $139B AUM 31.83% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Gradient Investments's NAVB Position: Q1 2020 in Review

Gradient Investments sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q1 2020, closing a stake of 31 shares.

Gradient Investments first reported a position in NAVB in Q4 2019 and held it in 1 quarter. The position peaked at $0 in Q4 2019. 29 funds tracked by Wall St. Rank hold NAVB as of Q1 2020.

  • Gradient Investments reported no remaining Navidea Biopharmaceuticals Inc. position as of Q1 2020 after selling out during the quarter.
  • Gradient Investments sold 31 Navidea Biopharmaceuticals Inc. shares in Q1 2020.
  • Gradient Investments first reported a position in Navidea Biopharmaceuticals Inc. in Q4 2019 and held it in 1 quarter.
  • Gradient Investments's Navidea Biopharmaceuticals Inc. position peaked at $0 in Q4 2019.
  • 29 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q1 2020.

Based on Gradient Investments's 13F filing for Q1 2020, filed 7 Apr 2020.